Latest Biotech News

Ginkgo Bioworks secured a four‑year, $47 million contract to design and integrate an automated phenotyping platform for Pacific Northwest National Laboratory (PNNL). The system will automate...

Terray Therapeutics reported it reached a discovery milestone under its multi-target collaboration with Bristol Myers Squibb, demonstrating its Experimentation Meets Machine Intelligence (EMMI)...

Two regulatory actions this week signaled growing scrutiny on gene‑therapy development. UniQure said FDA feedback indicates its Huntington’s gene therapy AMT‑130 will likely face a longer, more...

Biopharma financing through November shows a reversion toward normalized activity after pandemic-era volatility, with November’s $9.94 billion across 96 transactions trailing October but...

The CDC’s Advisory Committee on Immunization Practices voted to remove the standing universal recommendation that all newborns receive the hepatitis B vaccine within hours of birth. The 8–3 vote...

Tracey Beth Høeg, a physician and epidemiologist with prior critiques of COVID‑19 vaccine policy, was appointed acting director of the FDA’s Center for Drug Evaluation and Research. The move marks...

Freenome announced a SPAC merger expected to deliver roughly $330 million in proceeds, backed by a $240 million PIPE from institutional healthcare investors. The Bay Area developer is preparing...

Natera completed its acquisition of Foresight Diagnostics in a deal structured for $275 million up front with up to $175 million in earnouts, pairing Foresight’s phased‑variant PhasED‑Seq MRD...

Crescent Biopharma struck a bilateral deal with Sichuan Kelun‑Biotech to generate parallel datasets for its PD‑1/VEGF bispecific CR‑001 and to test combination strategies with antibody‑drug...

Praxis Precision Medicines stopped its Phase 2/3 EMBOLD study in developmental and epileptic encephalopathies early after an interim analysis showed strong efficacy for the sodium‑channel...

Bristol Myers Squibb received regulatory approval to expand the indication for its CAR‑T therapy Breyanzi to include third‑line marginal zone lymphoma, marking the first CAR‑T approval for this...

Syntax Bio reported research in Science Advances on its Cellgorithm platform, a CRISPR‑based system that programs gene activity in human stem cells to accelerate and standardize differentiation....

Researchers at MUSC Hollings Cancer Center published preclinical data showing that a monoclonal antibody targeting secreted frizzled‑related protein 2 (SFRP2) reduced primary triple‑negative...

Triana Biomedicines announced an oversubscribed $120 million Series B to advance its molecular glue degrader pipeline, including lead candidate TRI‑611 aimed at ALK‑driven non‑small cell lung...

Freenome agreed to merge with a SPAC to take the Bay Area liquid‑biopsy developer public with roughly $330 million in proceeds, including a $240 million PIPE commitment. The deal accelerates...

The Advisory Committee on Immunization Practices voted to remove the long‑standing universal hepatitis B vaccine recommendation at birth for infants whose mothers test negative, instead urging...

The FDA named Tracy Beth Høeg as acting director of the Center for Drug Evaluation and Research amid rapid leadership turnover at CDER. Høeg, an epidemiologist who worked on high‑profile vaccine...

Natera agreed to acquire Foresight Diagnostics for $275 million upfront plus up to $175 million in earnouts to integrate PhasED‑Seq phased‑variant technology into Natera’s Signatera MRD platform....

Royalty Pharma agreed to provide up to $275 million to Denali tied to potential approval of tividenofusp alfa, giving Denali contingent capital while the FDA delays a regulatory decision. The...

Triana Biomedicines closed an oversubscribed $120 million Series B to advance TRI‑611, a molecular‑glue degrader targeting ALK‑driven non‑small cell lung cancer, into clinical development. The...